stockrowProtalix BioTherapeutics, Inc.
PLXProtalix BioTherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $52.7 million, down 1.23% from fiscal 2024.
- Revenue
- +27.1%
- EPS
- +2,281.0%
- Free cash flow
- −94.1%
Quarter to June 2026, against a year earlier
Follow PLX
Alert me
Protalix BioTherapeutics, Inc. (PLX) Return on invested capital
Protalix BioTherapeutics, Inc.'s return on invested capital over the twelve months to 30 June 2026 was 48.5%, up 68.4 percentage points from fiscal 2025 (−19.9%). Over the past ten years it has ranged from −224.3% (fiscal 2015) to 29.2% (fiscal 2024); the current reading is higher than 18% of that period. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −19.9% | (49.13) |
| FY2024 | 29.2% | 29.21 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | 0.00 |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | 224.28 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| PLX Protalix BioTherapeutics, Inc. | 48.5% |
| PALI Palisade Bio, Inc. compare | 0.00% |
| RNAC Cartesian Therapeutics, Inc. compare | 0.00% |
| ARTV Artiva Biotherapeutics, Inc. compare | 0.00% |
| DRUG Bright Minds Biosciences Inc. compare | 0.00% |
| IKT Inhibikase Therapeutics, Inc. compare | 0.00% |
| ELDN Eledon Pharmaceuticals, Inc. compare | 0.00% |
| IFRX InflaRx N.V. compare | −87.3% |
| SLGL Sol-Gel Technologies Ltd. compare | −6,630.2% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)